IBI3042 / Innovent Biologics - LARVOL DELTA

A Study of IBI3042 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Fortvita Biologics (USA)Inc.

New P1 trial

IBI3042 Study in Healthy Participants and Overweight or Obese Participants (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants (clinicaltrials.gov) - P1 | N=94 | Not yet recruiting | Sponsor: Hongwei Jiang

New P1 trial • Genetic Disorders • Obesity

IBI3042 Study in Healthy Participants and Overweight or Obese Participants (clinicaltrials.gov) - P1 | N=104 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Genetic Disorders • Obesity

IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity (ADA 2026) - "Introduction and Objective: Peptide-based GLP-1 receptor agonists, such as Semaglutide, are highly effective for managing type 2 diabetes (T2D) and obesity but are limited by high costs and the need for injections. IBI3042 demonstrated robust, dose-dependent body weight reduction with twice-weekly oral dosing in DIO humanized GLP-1 receptor knock-in mice and confirmed once-weekly oral efficacy in obese cynomolgus monkeys. These preclinical data position IBI3042 as a promising once-weekly oral small-molecule GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity."

Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

ADA Reference: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity (Abstract No.: 2543-P) (PRNewswire) - "IBI3042 is potentially the world's first once-weekly oral small-molecule GLP-1 receptor agonist candidate entering clinical studies by the end of 2026...IBI3042 exhibited GLP-1R activation in cAMP assays, but showed no β-arrestin recruitment in NanoBiT assays. In human GLP-1 receptor knock-in (GLP-1R KI) mice, IBI3042 (0.4 mg/kg P.O.) maintained significant glucose-lowering effects for at least 7 days, outperforming Orforglipron at the same dose...In diet-induced obese (DIO) humanized GLP-1 receptor knock-in mice, IBI3042 at 1 mg/kg twice weekly showed comparable efficacy to Orforglipron 1.5 mg/kg once daily, while the 3 mg/kg twice-weekly dose demonstrated superior efficacy....In obese cynomolgus monkeys, IBI3042 produced robust, dose-dependent body weight reduction with twice-weekly oral dosing (1.5–4.5 mg/kg)."

New trial • Preclinical • Obesity • Type 2 Diabetes Mellitus

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions (PRNewswire) - "'The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032 (oral daily GLP-1 small molecule), IBI3042 (oral weekly GLP-1 small molecule), IBI3040 (amylin) and IBI3046 (INHBE siRNA) represent key milestones of our next‑generation obesity pipeline with global potential...'"

Clinical data • P3 data • Preclinical • Obesity • Type 2 Diabetes Mellitus